Zecuity Migraine Patches Associated with Scars, Burns Where Patch Was Applied

July 22, 2016 | Strategic Insights for Ambulatory Care


​The U.S. Food and Drug Administration (FDA) warned providers and consumers about the potential for scarring and burns related to the use of Zecuity migraine patches (a sumatriptan iontophoretic transdermal system), states a safety alert from FDA updated June 13, 2016. The agency states that the product's manufacturer has temporarily suspended sales, marketing, and distribution of the patches while it investigates the cause of burns and scars associated with use of the patches, an issue that FDA is also currently investigating.

Access Full Content

Contact us today at 610.825.6000.